Review maps protein-degrader progress and remaining evidence gaps in lymphoid cancers
Academic source · Expert Opinion on Emerging Drugs / PubMed
Source published:
Site published: 2026-11-08 · Updated: 2026-11-08
This source is linked automatically. Choose a question to get started.
What the paper reports
A review in Expert Opinion on Emerging Drugs surveys protein degraders for lymphoid malignancies, drawing on literature and major hematology meetings through April 2026. It discusses BTK degraders, STAT3 degradation, and molecular-glue approaches alongside early clinical activity. The authors identify unresolved questions around response durability, long-term safety, and predictive biomarkers; the article reports no new interventional trial.
Why this paper is included
Potential business implication: the review may guide target prioritization and biomarker planning, while its search cutoff limits interpretation of newer clinical developments.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections